Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Relevance of Pretransplant HLA Class II Donor-specific Antibodies in Renal Transplantation Patients with Negative T-cell Cytotoxicity Crossmatches

  • Song, Eun Young (Department of Laboratory Medicine, Seoul National University College of Medicine) ;
  • Lee, Yu-Joo (Department of Laboratory Medicine, Seoul National University College of Medicine) ;
  • Hyun, Jungwon (Department of Laboratory Medicine, Seoul National University College of Medicine) ;
  • Kim, Yon Su (Departmens of Internal Medicine, Seoul National University College of Medicine) ;
  • Ahn, Curie (Departmens of Internal Medicine, Seoul National University College of Medicine) ;
  • Ha, Jongwon (Department of Surgery, Seoul National University College of Medicine) ;
  • Kim, Sang Joon (Department of Surgery, Seoul National University College of Medicine) ;
  • Park, Myoung Hee (Department of Laboratory Medicine, Seoul National University College of Medicine)
  • Published : 2012.03.01
⟨ Previous Next ⟩

Abstract

Background: We evaluated the clinical relevance of pretransplant donor-specific HLA antibodies (DSA) in renal transplantation patients who had negative T-cell cytotoxicity crossmatches. Methods: From 328 consecutive renal transplant recipients, we selected 28 patients who had positive pretransplant (historical or at the time of transplantation) flow cytometry crossmatches, but negative T-cell cytotoxicity crossmatches at the time of transplantation. The presence of DSA and its level at the time of transplantation were retrospectively tested using Luminex single antigen assays. Results: DSA was present in 16 (57.1%) of 28 patients. Biopsy-proven acute rejection (9 patients) occurred more frequently in patients with DSA than in those without DSA (56.3% vs. 0.0%; P =0.003). The positivity rate of class II DSA was significantly higher in patients with antibody-mediated rejection (AMR) than in those without AMR (100% vs. 21.7%; P = 0.003). However, the positivity rate of class I DSA was not different between the two groups (40% vs. 40.9%). Among patients with class II DSA, those with AMR tended to have higher antibody levels (median fluorescence intensity, MFI) than those without AMR (16,359 vs. 5,910; P =0.056). A cut-off MFI value of 4,487 for class II DSA predicted the occurrence of AMR with good sensitivity and specificity (100% and 87.0%). Conclusions: In patients with negative T-cell cytotoxicity crossmatches, the presence of class II DSA and its level at the time of transplantation were associated with the occurrence of AMR. Pretransplant DSA measurement with Luminex single antigen assay would be useful in renal transplantation.

Keywords

References

  1. Gebel HM and Bray RA. Sensitization and sensitivity: defining the unsensitized patient. Transplantation 2000;69:1370-4. https://doi.org/10.1097/00007890-200004150-00027
  2. Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003;75:43-9. https://doi.org/10.1097/00007890-200301150-00008
  3. Lefaucheur C, Suberbielle-Boissel C, Hill GS, Nochy D, Andrade J, Antoine C, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008;8:324-31. https://doi.org/10.1111/j.1600-6143.2007.02072.x
  4. Amico P, Honger G, Mayr M, Steiger J, Hopfer H, Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009;87:1681-8. https://doi.org/10.1097/TP.0b013e3181a5e034
  5. Eng HS, Bennett G, Tsiopelas E, Lake M, Humphreys I, Chang SH, et al. Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss. Am J Transplant 2008;8:2335-42. https://doi.org/10.1111/j.1600-6143.2008.02387.x
  6. Gupta A, Iveson V, Varagunam M, Bodger S, Sinnott P, Thuraisingham RC. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant? Transplantation 2008;85:1200-4. https://doi.org/10.1097/TP.0b013e31816b1c37
  7. Aubert V, Venetz JP, Pantaleo G, Pascual M. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol 2009;70:580-3. https://doi.org/10.1016/j.humimm.2009.04.011
  8. Vlad G, Ho EK, Vasilescu ER, Colovai AI, Stokes MB, Markowitz GS, et al. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol 2009;70:589-94. https://doi.org/10.1016/j.humimm.2009.04.018
  9. Gloor JM, Winters JL, Cornell LD, Fix LA, DeGoey SR, Knauer RM, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010;10:582-9. https://doi.org/10.1111/j.1600-6143.2009.02985.x
  10. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010;21:1398-406. https://doi.org/10.1681/ASN.2009101065
  11. Reinsmoen NL, Lai CH, Vo A, Cao K, Ong G, Naim M, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008;86:820-5. https://doi.org/10.1097/TP.0b013e3181856f98
  12. Vaidya S, Cooper TY, Avandsalehi J, Barnes T, Brooks K, Hymel P, et al. Improved flow cytometric detection of HLA alloantibodies using pronase: potential implications in renal transplantation. Transplantation 2001;71:422-8. https://doi.org/10.1097/00007890-200102150-00015
  13. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999;55:713-23. https://doi.org/10.1046/j.1523-1755.1999.00299.x
  14. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003;3:708-14. https://doi.org/10.1034/j.1600-6143.2003.00072.x
  15. Pollinger HS, Stegall MD, Gloor JM, Moore SB, Degoey SR, Ploeger NA, et al. Kidney transplantation in patients with antibodies against donor HLA class II. Am J Transplant 2007;7:857-63. https://doi.org/10.1111/j.1600-6143.2006.01699.x
  16. Stastny P, Ring S, Lu C, Arenas J, Han M, Lavingia B. Role of immunoglobulin (Ig)-G and IgM antibodies against donor human leukocyte antigens in organ transplant recipients. Hum Immunol 2009;70:600-4. https://doi.org/10.1016/j.humimm.2009.04.017
  17. Issa N, Cosio FG, Gloor JM, Sethi S, Dean PG, Moore SB, et al. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008;86:681-5.
  18. Jin YP, Fishbein MC, Said JW, Jindra PT, Rajalingam R, Rozengurt E, et al. Anti-HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells. Hum Immunol 2004;65:291-302. https://doi.org/10.1016/j.humimm.2004.01.002
  19. Narayanan K, Jaramillo A, Phelan DL, Mohanakumar T. Pre-exposure to sub-saturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement-mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase/Akt pathway. Eur J Immunol 2004;34:2303-12. https://doi.org/10.1002/eji.200324843
  20. Salama AD, Delikouras A, Pusey CD, Cook HT, Bhangal G, Lechler RI, et al. Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. Am J Transplant 2001;1:260-9. https://doi.org/10.1034/j.1600-6143.2001.001003260.x
  21. Warner PR, Youngs D, Nelson KA. HLA density on microparticles versus antibody detection sensitivity: implications for crossmatch prediction. Hum Immunol 2007;68(S):S28.

Cited by

  1. Analysis of Anti-HLA Antibodies in Sensitized Kidney Transplant Candidates Subjected to Desensitization with Intravenous Immunoglobulin and Rituximab vol.96, pp.2, 2013, https://doi.org/10.1097/tp.0b013e3182962c84
  2. Sensitive Solid-Phase Detection of Donor-Specific Antibodies as an Aid Highly Relevant to Improving Allograft Outcomes vol.18, pp.2, 2012, https://doi.org/10.1007/s40291-013-0063-2
  3. Interlaboratory Comparison of the Results of Lifecodes LSA Class I and Class II Single Antigen Kits for Human Leukocyte Antigen Antibody Detection vol.35, pp.3, 2015, https://doi.org/10.3343/alm.2015.35.3.321
  4. Class I and II HLA antibodies in pediatric patients with thalassemia major vol.56, pp.4, 2016, https://doi.org/10.1111/trf.13440
  5. HLA and lung transplantation vol.13, pp.3, 2012, https://doi.org/10.1007/s11684-018-0636-x
  6. A novel approach reveals that HLA class 1 single antigen bead-signatures provide a means of high-accuracy pre-transplant risk assessment of acute cellular rejection in renal transplantation vol.20, pp.None, 2019, https://doi.org/10.1186/s12865-019-0291-2
  7. Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients vol.19, pp.10, 2012, https://doi.org/10.1111/ajt.15486